News
Alumis shoots up as its Sotyktu rival aces psoriasis trials
Alumis is preparing to file its oral TYK2 inhibitor envudeucitinib as a treatment for psoriasis later this year, after two positive phase 3 trials.
Thursday 30 April 2026
